Overview
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
Description
For Proton therapy with prostate adenocarcinoma patients.
Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks.
Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.
Eligibility
Inclusion Criteria:
- Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0
- ECOG performance status:0-1
- Signed study specific informed consent prior to study entry.
Exclusion Criteria:
- Postoperative residual or recurrent tumor
- Evidence of distant metastasis previous irradiation for the tumor in the same location
- Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)